Category: ScienceNews

When a disaster like a hurricane or wildfire destroys a house, the clock starts ticking. It gets harder for sick people to take their medications, medical devices may stop working without electricity, excessive temperatures, mold, or other factors may threaten someone's health. Every day without stable shelter puts people in danger.

The federal government is supposed to help prevent that cascade of problems, but an NPR investigation finds that the people who need help the most are often less likely to get it. NPR climate reporter Rebecca Hersher explains.

Check out Rebecca's full investigation here.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

A recent study published in Nature found that 37 percent of heat-related deaths are due to climate change. Dr. Renee Salas is seeing this in the emergency room of Massachusetts General Hospital. She's treating more and more patients for heat-related illnesses like heat stroke and intensified allergies. Today, she gives us a view into her work at the intersection of human health and climate change; plus, she envisions a new health care system that takes climate change into account.

To read more on this, see our episode page for links.

Reach the show by emailing shortwave@npr.org.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

As a kid, Ariana Remmel had a hard time figuring out where they fit in. So they found comfort in the certainty and understanding of what the world was made of: atoms and molecules and the periodic table of elements.

Years later, they went on to become a chemist and science writer. On today's show, Ari talks with host Maddie Sofia about how chemistry has helped them embrace their mixed identities.

For more, read Ari's recent essay in Catapult Magazine: 'Organic Chemistry Taught Me to Fully Inhabit My Mixed Identities.'

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

Early in the pandemic, contact tracing was viewed as one of the best options to quell the spread of coronavirus infections. The idea was to have public health workers track down people who tested positive, figure out whom they'd been in touch with and quickly get those people to quarantine. Places like Hong Kong and Singapore made headlines for their success stories. The U.S. aimed to replicate this, but came up short. Today, health reporter Selena Simmons-Duffin explains what went awry and the lessons learned.

Reach the show by emailing shortwave@npr.org.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

It took a while before it was officially recognised as a major symptom of Covid-19, but loss of smell has affected up to 60 percent of people who have had the virus. And for a significant portion, smell continues to be an issue for weeks or months after their recovery. So what’s going on and how can you get your sense of smell back?

We tend to think of our sense of smell as something universal – if it smells bad to me, it probably does to you but that is not the case for CrowdScience listener Annabel, who wonders why things other people love to sniff, she finds disgusting. Anand Jagatia investigates the science of smell, gets up close to the world’s smelliest plant and finds out if smell training can help those with long-term issues after Covid.

Contributors Ellie Byondin, supervisor of the Princess of Wales Conservatory at London’s Kew Gardens Thomas Hummel, University of Dresden Carl Philpott, from the UK’s Norwich Medical School Sissel Tolaas, artist and smell historian based in Berlin Noam Sobel, Weizmann institute of science

Presented by Anand Jagatia and Produced by Marijke Peters for the BBC World Service

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it.

For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."

You can email Short Wave at ShortWave@NPR.org.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

This week Jesse Bloom of Seattle’s Fred Hutchinson Cancer Research has published an account of some DNA sequence data he located in an internet archive, despite it having been removed from the US NIH’s Sequence Read Archive. He tells Roland Pease of its significance to our understanding of the beginning of the Covid pandemic, but also, of more general interest, to what it might tell scientists about the full availability of relevant virological evidence.

Elsewhere, Elena Zavala of the Max Planck Institute for Evolutionary Anthropology in Leipzig has been using new techniques for sequencing tiny fragments of mitochondrial DNA found in layers of mud to trace a long narrative of different evolutionary species of human and animal and their changing fortunes. As she describes in a paper published in Nature, sediments from different depths of the floor of the famous Denisova cave tell a long story of different humans (Denisovan and Neanderthal), bears, hyenas and other animals living there over different periods in the last 250 thousand years.

Over in the journal Science, several papers describe a new type of early hominin found in Nesher Rambla, Israel, that may be yet another instance of a human species that didn’t quite make it. As Marta Lahr, professor in human evolutionary biology at Cambridge University tells Roland the new findings all point to the bigger question – given the similar ages, technologies, and even neighbourhoods that all these types of hominin shared, just what was it about our own direct ancestor species that enabled us to take over the world?

Since almost the beginning of the Covid pandemic, in some parts of the world, the drug Ivermectin has been repurposed as a therapy against the disease, with some even believing it to convey protection against infection – a situation not without tragic consequences. The evidence for any meaningful effect has been less than obvious to most scientists and health authorities. Not the first controversial drug in the story of Covid-19, the discourse has led to abuse directed at scientists and officials, and scathing arguments across social media. As Oxford University’s PRINCIPLE trial this week begins to include Ivermectin in its investigations, BBC Reality Check’s Jack Goodman reports on the Ivermectin’s tortuous path.

(Image: Getty Images)

Presenter: Roland Pease Producer: Alex Mansfield

The past year has been the driest or second driest in most Southwestern U.S. states since record-keeping began in 1895. Climate Correspondent Lauren Sommer reports that farms and cities have begun imposing water restrictions, but the water supply will shrink no matter what the weather brings. The supply spans tens of millions of people and the farmland that produces most of the country's fruits and vegetables. As a result, the people who manage the West's complex water systems are realizing that with climate change, they can no longer rely on the past to predict the future.

Read more of Lauren's reporting.

Email us at shortwave@npr.org.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

Tam O'Shaughnessy and Sally Ride, the first American woman to fly in space, shared a passion for getting girls involved in STEM. It led them to co-found Sally Ride Science, a company focused on equity and inclusion in science education. But, there was much more to Tam and Sally's relationship. Tam gives us an intimate look at their decades-long partnership: how they met and fell in love, the pressures they faced as a queer couple, and their long-awaited and public coming out with Sally's death in 2012. We want to know which LGBTQ+ scientists have inspired you! Email the show at shortwave@npr.org.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy

Health Correspondent Allison Aubrey updates us on the Biden Administration's goal to have 70 percent of U.S. adults vaccinated by the July 4. Plus, as vaccine makers plan for the possibility that COVID-19 vaccine boosters will be needed, they're pushing ahead with research into new-generation flu shots and mRNA cancer vaccines.

Questions? Existential dread? Optimism? We'd love to hear it — write us at shortwave@npr.org.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy